6-K
GSK plc (GSK)
6-K
2025-03-28
For: 2025-03-28
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2025
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Charles Bancroft | |
| b) | Position/status | Senior Independent Non-Executive Director | |
| c) | Initial<br>notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br> <br><br><br>ISIN: US37733W2044 | |
| b) | Nature<br>of the transaction | Release of 17,446 notional ADSs from the GSK Non-Executive Director<br>Share Allocation Arrangements following the termination of those<br>arrangements, the withholding of 1,602 notional ADSs for tax and<br>the final release of 15,843 ADSs representing the balance. These<br>ADSs will be held by Charles Bancroft until he retires from the<br>Board. A residual cash payment of 32.60 will be paid to Charles<br>Bancroft. | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 15,843 | |||
| d) | Aggregated<br>information | N/A (single transaction) | |
| Aggregated<br>volume<br><br><br><br><br><br>Price | |||
| e) | Date<br>of the transaction | 2025-03-25 | |
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) |
All values are in US Dollars.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Dr Anne Beal | |
| b) | Position/status | Independent Non-Executive Director | |
| c) | Initial notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs')<br><br> <br><br><br>ISIN: US37733W2044 | |
| b) | Nature of the transaction | Release of 1,988 notional ADSs from the GSK Non-Executive Director<br>Share Allocation Arrangements following the termination of those<br>arrangements, the withholding of 1,018 notional ADSs for tax and<br>the final release of 970 ADSs representing the balance. These<br>shares will be held by Dr Anne Beal until she retires from the<br>Board. A residual cash payment of 4.66 will be paid to Dr Anne<br>Beal. | |
| c) | Price(s) and volume(s) | Volume(s) | |
| 970 | |||
| d) | Aggregated information | N/A (single transaction) | |
| Aggregated volume<br><br><br><br><br><br>Price | |||
| e) | Date of the transaction | 2025-03-25 | |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
All values are in US Dollars.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Dr Hal Dietz | |
| b) | Position/status | Independent Non-Executive Director | |
| c) | Initial notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs')<br><br> <br><br><br>ISIN: US37733W2044 | |
| b) | Nature of the transaction | Release of 1,760 notional ADSs from the GSK Non-Executive Director<br>Share Allocation Arrangements following the termination of those<br>arrangements, the withholding of 909 notional ADSs for tax and the<br>final release of 850 ADSs representing the balance. These shares<br>will be held by Dr Hal Dietz until he retires from the Board. A<br>residual cash payment of 38.42 will be paid to Dr Hal<br>Dietz. | |
| c) | Price(s) and volume(s) | Volume(s) | |
| 850 | |||
| d) | Aggregated information | N/A (single transaction) | |
| Aggregated volume<br><br><br><br><br><br>Price | |||
| e) | Date of the transaction | 2025-03-25 | |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
All values are in US Dollars.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Dr Jesse Goodman | |
| b) | Position/status | Independent Non-Executive Director | |
| c) | Initial notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs')<br><br> <br><br><br>ISIN: US37733W2044 | |
| b) | Nature of the transaction | Release of 13,924 notional ADSs from the GSK Non-Executive Director<br>Share Allocation Arrangements following the termination of those<br>arrangements, the withholding of 7,082 notional ADSs for tax and<br>the final release of 6,842 ADSs representing the balance. These<br>shares will be held by Dr Jesse Goodman until he retires from the<br>Board. A residual cash payment of 11.64 will be paid to Dr Jesse<br>Goodman. | |
| c) | Price(s) and volume(s) | Volume(s) | |
| 6,842 | |||
| d) | Aggregated information | N/A (single transaction) | |
| Aggregated volume<br><br><br><br><br><br>Price | |||
| e) | Date of the transaction | 2025-03-25 | |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
All values are in US Dollars.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: March<br>28, 2025 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |